{"name": "NeurAxon",
 "permalink": "neuraxon",
 "crunchbase_url": "http://www.crunchbase.com/company/neuraxon",
 "homepage_url": "http://www.nrxn.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2004,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "416-673-6697",
 "description": "",
 "created_at": "Wed Dec 30 10:35:56 UTC 2009",
 "updated_at": "Wed Nov 03 17:27:38 UTC 2010",
 "overview": "\u003Cp\u003ENeurAxon, Inc. discovers and develops pain therapeutics targeting neuronal nitric oxide synthase. It has oral products in pipeline addressing acute migraine, neuropathic pain chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. The company was founded in 2004 and is headquartered in Toronto, Canada.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       59],
      "assets/images/resized/0007/1568/71568v1-max-150x150.png"],
     [[250,
       98],
      "assets/images/resized/0007/1568/71568v1-max-250x250.png"],
     [[279,
       110],
      "assets/images/resized/0007/1568/71568v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Lawrence",
      "last_name": "E. Bloch",
      "permalink": "lawrence-e-bloch",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$22.8M",
 "funding_rounds":
  [{"round_code": "debt_round",
    "source_url": "http://www.masshightech.com/stories/2009/12/28/daily13-NeurAxon-nabs-875M-in-debt-funding.html",
    "source_description": "NeurAxon nabs $8.75M in debt funding",
    "raised_amount": 8750000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 12,
    "funded_day": 30,
    "investments":
     []},
   {"round_code": "debt_round",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=29\u0026aid=DJFVLS0020100930e69u0005o\u0026r=Rss\u0026s=DJFVLS",
    "source_description": "  \t  NeurAxon Raises $14M Convertible Debenture Financing",
    "raised_amount": 14000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 9,
    "funded_day": 30,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "480 University Avenue ",
    "address2": "Suite 900 ",
    "zip_code": "M5G 1V2",
    "city": "Toronto, ON",
    "state_code": null,
    "country_code": "CAN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "NeurAxon Inc. said that while a Phase 2 clinical trial for its drug candidate to treat migraines did not meet its primary endpoint, the potential drug did show significant pain relief for patients",
    "stoned_year": 2010,
    "stoned_month": 11,
    "stoned_day": 1,
    "source_url": "http://www.masshightech.com/stories/2010/11/01/daily5-NeurAxon-migraine-drug-returns-mixed-results.html",
    "source_text": null,
    "source_description": "NeurAxon migraine drug returns mixed results",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "NeurAxon",
      "permalink": "neuraxon"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        82],
       "assets/images/resized/0007/1567/71567v1-max-150x150.jpg"],
      [[250,
        137],
       "assets/images/resized/0007/1567/71567v1-max-250x250.jpg"],
      [[450,
        246],
       "assets/images/resized/0007/1567/71567v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}